Affidea wins "Diagnostics and Primary Care" Award at the prestigious LaingBuisson Health Awards


23/11/2022

Madrid, November 23, 2022: Affidea, Europe's largest provider of advanced diagnostics, outpatient and cancer treatment services, is pleased to announce that the company has won this year's LaingBuisson Health "Diagnostics and Primary Care" award.

The LaingBuisson Awards are one of the most prestigious awards in healthcare and honor companies that set new standards of excellence and make an impact in their category. This year marks the 17th year recognizing excellence in healthcare, focusing on healthcare providers and their consultants.

Affidea won the award in this category for its innovative Dose Excellence Program for patient safety. Through this program, the company analyzes data from more than 75,000 computed tomography (CT) scans each month, achieving an average 40% reduction in radiation dose level in CT scans across its network to increase patient safety while maintaining image quality for accurate diagnosis.

Affidea has recently taken the program to the next level with the release of a 3.2 version of the DoseWatch software, in combination with a real-time business intelligence (BI) tool for data dashboarding, with Affidea centers in Spain and Hungary being the first to implement it.

The next step of the project is contrast media data management, which allows receiving notifications about the clinical context and cumulative iodine dose (risk factors, previous adverse events), as well as injection details (contrast media, volume, injection protocol). Thanks to contrast media tracking and optimization, the company can customize the contrast injection for each patient, avoiding unnecessary extra contrast injection.

Guy Blomfield, Chairman of the Supervisory Board and CEO of Affidea, says: "It is an honor to receive this prestigious award. This is a testament to all of our efforts and achievements in providing exceptional patient safety by implementing strict clinical protocols and innovative tools. I want to thank all our amazing and dedicated clinic teams, and especially the members of the Dose Excellence team, for all their passion, commitment and hard work behind the scenes. This award recognizes the extremely high quality of their work and I couldn't be prouder of this."

Dr. Alessandro Roncacci, Senior Medical Director, adds, "This is another proof of our strong compliance with Euratom Directive 2013/59 by identifying real-time variations and standardizing and optimizing CT protocols, maintaining gold standards in image quality and increased safety for our patients. By 2023 we have high ambitions to roll out the new version of our Dose Excellence Program in all Affidea countries, guided by our strong commitment to the highest standards of patient safety."

Theo Kravvas, Country manager of Affidea Spain, adds: "This is a further demonstration of the company's commitment to quality. It is a source of pride and motivation that, both globally and in each country, we all pursue excellence in patient care and safety."

The awards ceremony took place at Park Westminster Bridge and was attended by more than 1,000 key figures from the independent healthcare sector.

The award is Affidea's second this year. In June, the company was awarded Diagnostics Provider of the Year at the HealthInvestor Awards 2022.

About Affidea Group

Affidea Group (www.affidea.com) is Europe's largest provider of advanced diagnostic imaging, outpatient and cancer treatment services. With 329 medical centers in 15 countries across Europe, Affidea provides advanced diagnostic, outpatient and cancer care services to more than 12 million patients a year. Thanks to its track record in patient safety, Affidea is the most awarded medical imaging provider in Europe by the European Society of Radiology: more than half of the centers awarded in the Eurosafe Wall of Stars are Affidea centers.

Affidea Group media contact: Oana Dumitroiu - +40 738 674 320 - oana.dumitroiu@affidea.com

Affidea Spain

Affidea España (www.affidea.es) is a leading medical provider in diagnostic imaging, nuclear medicine and outpatient medical specialties, with 43 centers nationwide. Affidea España performs more than 900,000 diagnostic imaging examinations each year, offering a medical service of excellence at the forefront of patient care. The company works with more than 1,100 professionals. Affidea Spain is recognized for its focus on patient safety, having all its centers accredited for excellence in nuclear medicine by the European Union of Medical Specialties (UEMS) and the European Board of Nuclear Medicine (EBNM).

Media contact: Elena Ayuso - 656 321 906 - elena.ayuso@affidea.com - ES_prensa@affidea.com